Economy/Home · Economy

[IPO HOT] Nexai to List on KOSDAQ on the 12th... Offering Price of 8,000 Won Falls Below Desired Band; Technology Transfer and Clinical Results Face a Test

Nexai to Enter KOSDAQ on the 12th... Offering Price Set at 8,000 Won Nexai (493410), a new drug development company, will enter the KOSDAQ market on the 12th. Nexai is a biotech company engaged in pharmaceutical manufacturing and is developing new treatments for cancers that do not respond sufficie

Wooil Shim
Staff Reporter
11 min read
[IPO HOT] Nexai to List on KOSDAQ on the 12th... Offering Price of 8,000 Won Falls Below Desired Band; Technology Transfer and Clinical Results Face a Test
CBC News

Nexai to Enter KOSDAQ on the 12th... Offering Price Set at 8,000 Won

Nexai (493410), a new drug development company, will enter the KOSDAQ market on the 12th. Nexai is a biotech company engaged in pharmaceutical manufacturing and is developing new treatments for cancers that do not respond sufficiently to immuno-oncology agents.

■ Offering Price of 8,000 Won... 23.81% Below the Bottom of the Desired Band

In this public offering, Nexai is offering a total of 5 million shares to raise 40 billion won. The initially desired offering price range was 10,500 to 13,000 won, but the final offering price was set at 8,000 won, 2,500 won below the bottom of the range. This is about 23.81% lower than the bottom and about 38.46% lower than the top of the desired range.

In the demand forecast, the competition ratio for institutional investors was recorded at 66.58 to 1. Retail investor subscriptions were conducted through Korea Investment & Securities, with 56,990 subscription applications counted. Subscription-related competition ratios were presented at 25.52 to 1 and 13.26 to 1, respectively, though the specific breakdown of these two figures requires further confirmation. The number of shares allocated to retail investors is between 1.25 million and 1.5 million.

■ NEXORA™ Platform... From Identifying Factors Behind Non-Responsive Cancers to ADCs

Nexai's NEXORA™ platform is a technology that analyzes the characteristics of cancers that do not respond to immuno-oncology treatments to identify the causative factors driving treatment resistance. Nexai searches for factors involved in treatment non-responsiveness by combining its own non-clinical refractory cancer models with a clinical specimen analysis database. It then establishes development priorities through quantitative and functional validation, and designs neutralizing antibody therapeutics suited to the relevant targets. Alongside drug development, the company is also pursuing a precision medicine approach by discovering biomarkers that take individual patient characteristics into account.

Notably, the NEXORA™ platform has expanded its development scope beyond antibody therapeutics into the field of antibody-drug conjugates (ADCs), focusing on securing anti-cancer drug candidates that utilize different mechanisms of action.

■ NXI-101, Licensed to Ono Pharmaceutical... Commercialization Potential Hinges on Clinical Results

Among the key candidates, NXI-101 has been licensed to Japanese pharmaceutical company Ono Pharmaceutical (ONO Pharma). NXI-101 is an antibody-based new drug candidate targeting regulatory factors involved in the tumor microenvironment (TME) of cancers that do not respond to immuno-oncology treatments. Nexai highlights the fact that NXI-101 led to a global technology transfer agreement at the non-clinical development stage as a major commercialization achievement.

Ono Pharmaceutical is a Japanese pharmaceutical company with experience in developing and commercializing the immuno-oncology drug Opdivo. However, the signing of a technology transfer agreement and the ultimate success of drug development should be distinguished from each other, as the candidate's commercialization potential may vary depending on future clinical trial results and development timelines.

■ NXI-201, U.S. FDA Phase 1 Clinical Trial Approval... Significance and Limitations

The clinical development of the follow-up candidate NXI-201 is also drawing attention. NXI-201 received approval for its Phase 1 clinical trial plan from the U.S. FDA on August 3, 2026. The development target is advanced or metastatic solid tumors. The clinical trial will assess the safety and tolerability of the candidate and evaluate its efficacy.

NXI-201's entry into clinical trials is significant in that Nexai advanced a candidate discovered through its own platform—from non-clinical research and pharmaceutical manufacturing and quality control (CMC) development—to the stage of human trials. However, entering Phase 1 does not in itself guarantee therapeutic efficacy or final product approval. Safety and efficacy data obtained from actual clinical trials will serve as key criteria for subsequent development.

■ From Early Listing Supply-Demand to Clinical Progress... Variables for Mid- to Long-Term Value Assessment

Based on its experience with the NXI-101 technology transfer, Nexai plans to continue research and development of follow-up candidates, including NXI-201, and pursue global commercialization activities. Attention is focused on how the market will evaluate the investment demand confirmed during the offering process and the company's technological achievements as a new drug developer, in connection with its KOSDAQ listing on the 12th. In particular, as the company enters the stock market at a price lower than its desired offering range, not only early listing supply and demand but also clinical development progress and follow-up technology transfer outcomes are expected to act as key variables in assessing its mid- to long-term corporate value.

[Some AI assistance was used in the preparation of this article. This article does not recommend the purchase or sale of any specific stock, and investment decisions and responsibilities rest with the investor.]

Wooil Shim
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.